| CAS NO: | 428863-50-7 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| Cas No. | 428863-50-7 |
| 别名 | 赛妥珠单抗,Certolizumab; CDP870 |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research[1][2]. Certolizumab pegol (Certolizumab) neutralizes soluble TNFα with an IC90 of 3 ng/mL[2].Certolizumab pegol (0-100 μg/mL, 1 h) completely inhibits subsequent production of IL-1β in response to LPS at concentrations over 1μg/mL in human monocytes[2].Certolizumab pegol does not mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC)[2].Certolizumab pegol does not induce apoptosis of activated human monocytes or peripheral blood lymphocytes (PBLs) or result in degranulation or loss of cell membrane integrity in polymorphonuclear cells[2]. Certolizumab pegol (Certolizumab) (10 μg; i.p.; single dose) reduces the severity of acute pancreatitis[3]. [1]. Deeks ED. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. Drugs. 2013 Jan;73(1):75-97. |
m.cnreagent.com